89bio, Inc. announced that data from the 48-week extension phase of the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis with fibrosis.
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Canada needs a robust domestic pharmaceutical industry ipolitics.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ipolitics.ca Daily Mail and Mail on Sunday newspapers.